Accéder au contenu
Merck

Protoporphyrin IX accumulation disrupts mitochondrial dynamics and function in ABCG2-deficient hepatocytes.

FEBS letters (2013-08-21)
Yu-Hsing Lin, Hsiao-Min Chang, Fang-Pei Chang, Chia-Rui Shen, Chao-Lin Liu, Wan-Yu Mao, Chung-Chih Lin, Hsuan-Shu Lee, Chia-Ning Shen
RÉSUMÉ

Targeted inhibition of multidrug ABCG2 transporter is believed to improve cancer therapeutics. However, the consequences of ABCG2 inhibition have not been systematically evaluated since ABCG2 is expressed in several organs including the liver. Here, we demonstrate that ABCG2-deficient hepatocytes have increased amounts of fragmental mitochondria accompanied by disruption of mitochondrial dynamics and functions. This disruption was due to ABCG2 knockout elevating intracellular protoporphyrin IX, which led to upregulation of DRP-1-mediated mitochondrial fission. The finding that ABCG2 deficiency can generate dysfunctional mitochondria in hepatocytes raises concerns regarding the systematic use of ABCG2 inhibitor in cancer patients.

MATÉRIAUX
Numéro du produit
Marque
Description du produit

Sigma-Aldrich
Protoporphyrin IX, ≥95%
Sigma-Aldrich
Glycogène from oyster, ≥75% dry basis
Sigma-Aldrich
Glycogen from bovine liver, ≥85% dry basis (enzymatic)
Sigma-Aldrich
Glycogen from mussel, Mytilus genus, for DNA precipitations
Sigma-Aldrich
Protoporphyrin IX disodium salt, ≥90% (HPLC)
Sigma-Aldrich
Glycogen from rabbit liver, ≥85% dry basis (enzymatic)
Sigma-Aldrich
Glycogen from mussel, Mytilus genus, ≥85% anhydrous basis (enzymatic)